In medical news:

An analysis of federal data from IMS Health has revealed that moving Vicodin and similar products from schedule III to the more restrictive schedule II on the federal controlled substances list was associated with 1.1 billion fewer tablets and 26.3 million fewer prescriptions for the drugs in the first year following the change, according to the Department of Health and Human Services. Former and current FDA officials published the results online in JAMA Internal Medicine, noting that in the three years prior to the rescheduling, use was already on its way down, with prescriptions dropping by 8.4 percent and total tablets dispensed dropping by 6 percent. But a year after the move, the decline accelerated – with prescriptions falling by 22 percent and tablets by 16 percent.

Read more from MedPage Today here.

Leave a Comment

Your email address will not be published. Required fields are marked *